Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ: TSVT )

9.210 -0.240 (-2.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 374,250
Open 9.340
Bid (Size) 9.200 (40)
Ask (Size) 9.940 (1)
Prev. Close 9.450
Today's Range 9.210 - 9.570
52wk Range 8.440 - 19.33
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2seventy bio's Return On Capital Employed Overview
 
Via Benzinga
Wedbush Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know
 
Via Benzinga

Performance

YTD
-0.86%
-0.86%
1 Month
-32.97%
-32.97%
3 Month
+7.22%
+7.22%
6 Month
-33.55%
-33.55%
1 Year
-49.00%
-49.00%

More News

Read More
Where 2seventy bio Stands With Analysts
Via Benzinga
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference
From 2seventy bio, Inc.
Via Business Wire
SVB Leerink Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know
Via Benzinga
Expert Ratings for 2seventy bio
Via Benzinga
2seventy bio Announces Pricing of Upsized Public Offering of Common Stock
From 2seventy bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
2seventy bio Announces Proposed Public Offering of Common Stock
From 2seventy bio, Inc.
Via Business Wire
Week in Review: VectorBuilder Raises $57 Million for Gene Therapy Delivery CDMO
Via Talk Markets
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
Via Benzinga
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
From Bristol Myers Squibb
Via Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Provides Company Outlook for 2023
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
From 2seventy bio, Inc.
Via Business Wire
4 Analysts Have This to Say About 2seventy bio
Via Benzinga
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Via Benzinga
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients
From 2seventy bio, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.